FUJIFILM Irvine Scientific Launches BalanCD Gal Supplement for Biotherapeutic Development


FUJIFILM Irvine Scientific, Inc. recently introduced BalanCD Gal Supplement. The new formula has been developed to increase galactosylation in biotherapeutic development, to help achieve desired glycan profiles for improved product quality and antibody efficacy.

Glycosylation is a critical aspect in development and optimization of protein-based therapeutics. The type and level of glycosylation can significantly affect antibody binding, function, and therapeutic efficacy. Galactosylation (the glycosylation of galactose) is a key method for controlling product quality due to the significant impact it has on antibody function, and the ability to control levels of galactosylation through the cell culture medium.

BalanCD Gal Supplement is a chemically-defined, animal component-free formula designed to increase N-linked galactosylation with a scalable protocol, offering researchers a simple method to control the process through the cell culture medium. The supplement is effective at low concentrations and is compatible with any basal growth medium.

BalanCD Gal Supplement has been developed as part of the BalanCD CHO media platform – an extended portfolio of chemically-defined, animal component-free growth and feed media formulated using Rational Culture Media Design. This multidimensional approach uses sequential, complementary development methods to leverage FUJIFILM Irvine Scientific scientists’ expertise in the effects of components and process parameters. The result is a media platform that delivers the precise combination of nutrients to maximize productivity, growth, and viability of CHO cell lines.

“The BalanCD Gal Supplement has been designed to incorporate seamlessly into our BalanCD media portfolio, providing researchers in biotherapeutic development with a holistic, efficient growth and production platform. Developed by our expert research and development group, the new supplement supports scientists in streamlining workflows, ultimately to advance emerging therapies,” said Robert Newman PhD, Chief Scientific Officer, FUJIFILM Irvine Scientific.

FUJIFILM Irvine Scientific, Inc., is a worldwide leader in the innovation and manufacture of cell culture media, reagents, and medical devices for researchers and clinicians. The company provides unrivaled service and quality to scientists working in biopharmaceuticals, cell therapy and regenerative medicine, assisted reproductive technology and cytogenetics, and industrial cell culture for the large-scale production of biotherapeutics and vaccines. FUJIFILM Irvine Scientific adheres to both ISO and FDA regulations and operates dual cGMP manufacturing facilities in California, USA, and Tokyo, Japan. The company’s consultative philosophy combined with expertise in cell culture and compliance provides customers with unique capabilities and support. For over 45 years, FUJIFILM Irvine Scientific has remained uniquely flexible and focused on media while becoming a strategic global leader in media products and services. FUJIFILM Irvine Scientific, Inc. is a subsidiary of FUJIFILM Holdings America Corporation reporting to FUJIFILM Holdings Corporation.

FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2019, the company had global revenues of $22 billion, at an exchange rate of 111 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.

Share This